Summary of Conference Call Company Overview - The company is a key provider of discovery, development, and commercialization reagents for next-generation therapeutics and diagnostics, finishing 2025 with $40.5 million in revenue, representing a 7% growth [1] - The company has over 3,000 active customers, including notable clients like Amgen, and has seen a 25% growth in clinical customer base, now supporting 60 clinical customers and over 70 therapies in clinical trials [1][2] Revenue Breakdown - 24% of revenue comes from cell and gene therapy, with expectations for significant milestones in 2026 and 2027 [2] - The revenue distribution includes: - 50% from biopharma (including CDMOs, biotech, and large pharma) - 30% from tools and diagnostics - 15% from a diverse range of customers including academic, food, and animal health - 5% from non-product revenue [3] Product Categories - The business is divided into two main categories: - **Lab Essentials**: Represents 75% of total revenue, primarily research use only products, with 80% of this being catalog products that are shipped within a day [4][5] - **Clinical Solutions**: Comprises 25% of revenue, with 90% being custom products made under GMP conditions [5] Competitive Advantages - The company differentiates itself through: - A strong link between research and commercial therapeutics, allowing for predictable and stable revenue from Lab Essentials [5] - Ability to handle small batch sizes cost-effectively, which is a growing need in diagnostics and therapeutics [7][8] - Fast turnaround times for custom formulations, often within a week compared to competitors [8][9] - Dynamic capacity to switch between catalog and custom products, optimizing manufacturing resources [11][12] Financial Performance and Projections - The company has maintained revenue despite a challenging market, with a significant reduction in workforce (50% decrease) leading to narrowed losses [22] - Expected to achieve adjusted EBITDA positivity by the end of 2027, with projected revenue between $52 million and $57 million [22] - Each new dollar of revenue is anticipated to contribute about 70% to the bottom line, with gross margins expected to reach 55%-60% as the business scales [23][25] Market Trends and Investments - The company is investing $2 million into expanding its sales force and marketing efforts, indicating confidence in market recovery and growth potential [26] - Biotech funding trends are closely monitored, with a historical lag of 3-4 quarters between funding increases and revenue growth [28] - The company is exploring M&A opportunities and geographic expansion, particularly in Europe, to enhance its product offerings and market reach [29] Customer Base and Growth Strategy - The top 10 customers account for only 18% of revenue, indicating a diverse customer base [18] - The growth strategy focuses on onboarding new clinical customers and expanding existing relationships, particularly in the Clinical Solutions segment [49][50] Conclusion - The company is positioned for significant growth with a solid foundation in its Lab Essentials business and an expanding Clinical Solutions segment, aiming for 20%-25% top-line growth and strong profitability in the coming years [31]

Table of Contents As filed with the Securities and Exchange Commission on August 23, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ALPHA TEKNOVA, INC. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 8731 94-3368109 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 245 ...